SAN DIEGO, Dec. 20, 2021 (GLOBE NEWSWIRE) -- CB Therapeutics today announces the appointments of Dr. Stephen Wright and Dr....
Helsinn and Xediton sign exclusive license and distribution agreement for TRUSELTIQ™ (infigratinib) in Canada Lugano, Switzerland, and Mississauga, Ontario, 20...
Treatment for Hepatitis C Virus (HCV) is effective in over 95% of infected patients, yet remains disproportionately unavailable to certain...
Exclusive license to anti-CCR8 monoclonal antibody program further strengthens FibroGen’s preclinical development pipelineHiFiBiO to receive $35 million option exercise payment,...
Study remains ongoing; top-line data anticipated in Q1 2022 versus near the end of the yearNEW YORK, Dec. 20, 2021...
EMERYVILLE, Calif., Dec. 20, 2021 (GLOBE NEWSWIRE) -- Zogenix (Nasdaq: ZGNX), a global biopharmaceutical company developing and commercializing rare disease...
SAN DIEGO, Dec. 20, 2021 (GLOBE NEWSWIRE) -- Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a precision oncology company developing next-generation...
LONDON, Dec. 20, 2021 (GLOBE NEWSWIRE) -- Achilles Therapeutics plc (NASDAQ: ACHL), a clinical-stage biopharmaceutical company developing precision T cell...
Company has enrolled 10 of the targeted 16 patients in the trial Anticipates interim data in mid-2022 and topline data...
- Approved for all eligible indications of the reference biological product, Humira® (adalimumab) - - YUSIMRY is Coherus' second FDA-approved...
Company retains iiiNTENT SAAS artificial intelligence marketing service for Tollovid® and Tollovid Daily™ 3CL protease inhibitor dietary supplement products NEW...
re+PLAY(TM) re+PLAY(TM) - a Harrington Wellness product re+PLAY is a sports performance and recovery-focused brand founded by NBA veteran Al...
CELEBRATION, Fla., Dec. 20, 2021 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NasdaqGS: KMPH), a specialty pharmaceutical company focused on the discovery and...
VBL is among only 9% of companies across industries selected by the EIC Accelerator Funds to be used for clinical...
JI XING to Develop and CommercializeNovel Cardiac Myosin Activator in Patients with Heart Failure Cytokinetics to Receive $70 Million in...
-- Clinical development of the MYC repressor APTO-253 will be discontinued -- -- Company will focus on advancing kinome inhibitor...
CAMBRIDGE, Mass., Dec. 20, 2021 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ: NTLA), a leading genome editing company focused on...
Company to Also Host Fireside Chat at the 24th Annual ICR Conference on January 10, 2022NEW YORK and LEAMINGTON, Ontario,...
Product is now available exclusively through Anovo specialty pharmacyProduct is stable at room temperature while Carbaglu® requires refrigerationEton Cares patient...
VANCOUVER, British Columbia, Dec. 20, 2021 (GLOBE NEWSWIRE) -- InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (Nasdaq: INM), a leader...
